Lambert et al., "Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor
osteoprotegerin in the colon of Crohn's disease patients," Clinical and Experimental Immunology, vol.
Moon, "Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor [kappa]B,
osteoprotegerin, and receptor activator of nuclear factor [kappa]B ligand," Arthritis & Rheumatism, vol.
Native human
osteoprotegerin amino acid sequence, N-terminal signaling peptide (gray) 1 mnkllccalv fldisikwtt qetfppkylh ydeetshqll cdkcppgtyl kqhctakwkt 61 vcapcpdhyy tdswhtsdec lycspvckel qyvkqecnrt hnrvceckeg ryleiefclk 121 hrscppgfgv vqagtpernt vckrcpdgff snetsskapc rkhtncsvfg llltqkgnat 181 hdnicsgnse stqkcgidvt lceeaffrfa vptkftpnwl svlvdnlpgt kvnaesveri 241 krqhssqeqt fqllklwkhq nkdqdivkki iqdidlcens vqrhighanl tfeqlrslme 301 slpgkkvgae diektikack psdqilklls lwrikngdqd tlkglmhalk hsktyhfpkt 361 vtqslkktir flhsftmykl yqklflemig nqvqsvkisc 1 Purified hOPG functional assessment via OPG--RANKL complex formation
Ng et al., "Rapamycin increases neuroblastoma xenograft and host stromal derived
osteoprotegerin inhibiting osteolytic bone disease in a bone metastasis model," Journal of Pediatric Surgery, vol.
Kiyoshima et al., "In situ expression of RANKL, RANK,
osteoprotegerin and cytokines in osteoclasts of rat periodontal tissue," Journal of Periodontal Research, vol.
Wang, "The effect of alendronate on the expression of osteopontin and
osteoprotegerin in calcified aortic tissue of the rat," European Journal of Pharmacology, vol.
Karan, "
Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis," Stroke, vol.
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
Increased levels of bone remodeling biomarkers (
osteoprotegerin and osteopontin) in hypertensive individuals.
Relation of
osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study).
RANKL also binds to
osteoprotegerin (OPG), a decoy receptor, which reduces resorption.
RANK-L is counteracted by naturally occurring
osteoprotegerin (OPG), another TNF family member that binds and subsequently prevents activation of its single cognate receptor, RANK, thus, making osteoclastic activity dependent on the balance between both RANK-L as well as OPG [39].
